Medical Audit

The cost of chronic dialysis in multiple myeloma

R.A. Coward

Department of Renal Medicine, Royal Preston Hospital, Sharoe Green Lane, Preston, UK.

Summary: The complications and costs of chronic dialysis in 4 patients with renal failure due to multiple myeloma are presented. In three patients the paraprotein responded to chemotherapy though without recovery of renal function. These three patients are alive after 18, 16 and 15 months of dialysis, the other dying after 7 months. Hospital admissions ranged from 26 to 74 days per year with infections accounting for 54 to 87% of admission days, 62.5% of which occurred during the first three months of dialysis treatment, with an incidence of 2.4 to 6.9 admissions episodes per year.

An in-house audit of our chronic dialysis patients indicated that treatment of myeloma patients is 5–33% more expensive. The extra cost in such high risk patients is mostly due to the greater number and longer duration of hospital admissions for infection. The other extra costs (in decreasing value) of blood products, antibiotics and chemotherapy are relatively small in comparison to in-patient treatment.

Introduction

Several published series have demonstrated that patients with severe chronic renal failure secondary to multiple myeloma can be successfully dialysed.^{1–3} Such patients would otherwise have died of renal failure rather than myeloma. There is little published information on the complications encountered by the myeloma patients on chronic dialysis and hence the cost of offering such treatment.

Bacterial infections are a major cause of morbidity and mortality in myeloma patients,⁴ with azotaemia being suggested as a further independent risk factor to increase the infection risk.⁵ Patients suffering from myeloma are often elderly (> 55 years of age) and hence would be classed as high risk dialysis patients independent of the systemic disease from which they suffer.⁶ They would also be unsuitable for renal transplantation. Such restraints imply a more difficult and expensive treatment regime.

In the modern climate of medical care in the United Kingdom, increasing emphasis has been placed, not on what is technically possible, rather what is feasible within limited health care resources.⁷ Though chronic renal failure programmes have received preferential treatment, the acceptance rate within the United Kingdom is still amongst the lowest in Europe.⁸ It is against this background that this paper examines the medical, economic and social implications of offering dialysis treatment to such high risk patients. We try and answer the questions: Is it justifiable to use long

term dialysis to keep such patients alive? Do these patients have a good quality of life? How much more does it cost to treat these patients than normal dialysis patients? What causes this difference?

Materials and methods

Patients

During the two year period from August 1985 to August 1987, four patients suffering from myeloma and severe renal failure were offered chronic dialysis at the Royal Preston Hospital. All patients had multiple myeloma based on the MRC criteria.⁹

All patients presented with severe renal failure (serum creatinine > 295 $\mu\text{mol/l}$). In 3, dialysis was not deemed necessary from between 2 and 7 months from presentation when initial treatment was by haemodialysis, though one patient (number 4) was subsequently trained for continuous ambulatory peritoneal dialysis (CAPD), the remaining three being on a hospital maintenance haemodialysis programme.

Chemotherapy

All patients had intermittent chemotherapy dependent on blood count. The different regimes used were: patient 1 – intravenous vincristine, adriamycin and oral dexamethasone.¹⁰ Prophylactic co-trimoxazole one twice daily, ketoconazole 600 mg and cimetidine 400 mg twice daily, were given for 7 days with each

Correspondence: R.A. Coward, D.M., M.R.C.P.
Accepted: 30 November 1988

course.¹¹ Patient 2 was entered into the MRC Vth Myeloma trial, being drawn to receive the ABCM protocol (6-week cycle, i.v. adriamycin and BiCNU, oral melphalan and cyclophosphamide). Patients 3 and 4 were treated with oral melphalan and prednisolone.

Costing

Drug costs were based on hospital contract prices including value added tax. Blood product costings were according to Department of Health and Social Security (DHSS) circular H.N. (87)15. In-patient (acute medicine) fully inclusive costs of £77.19 per day were based on the DHSS estimates. (DHSS Circular, Financial Matters, July 1987 [FMN7/87]). This was collated from a set of speciality costs by regression analysis from the 1985–86 costing returns from each health district in the United Kingdom. A prospective internal audit over 3 months on the Royal Preston Hospital Dialysis Unit with 20 maintenance haemodialysis and 19 CAPD patients, gave a cost of £110 per maintenance haemodialysis treatment and £19.32 for four 2-litre CAPD exchanges per day (unpublished data). This includes all staff salaries (medical, nursing, paramedical, administration, catering, pathology and radiology) and all consumables.

Antibiotics

First line treatment for patients with clinical evidence of a severe infection was 10 days' intravenous gentamicin and piperacillin. For subclavian line infection, the line was removed and intravenous vancomycin 1 g was given, to be followed by a 7-day course of oral flucloxacillin. Herpes was treated with acyclovir. Peritonitis during CAPD was treated with 10 days of intraperitoneal vancomycin and gentamicin.

Results

Response to chemotherapy

In all patients urinary light chain excretion became an unreliable indicator of disease activity because of oligoanuria. In two patients (numbers 2 and 4), the serum paraprotein was no longer detectable by immunoelectrophoresis and patient 3 showed a maximum 23% decrease in serum paraprotein.

These results indicate that patients 2, 3 and 4 responded to chemotherapy. However, patient 1 had clinical evidence of continuing amyloid deposition, and hence lack of response.

Three of the patients are still alive on chronic dialysis (August 1988 – all > 15 months dialysis). Patient 1 died 10 months after presentation and 7 months after commencing dialysis. The cause of death was bronchopneumonia complicated by amyloid.

Admissions

Though patient 4 had the largest total number of days in hospital (87), 39 of these days were explained by 'CAPD training', prolonged because of drug allergy, hypotension and oedema. Excluding CAPD training, the admissions for the four patients were from 26 to 74 days per year (Table I). The first 3 months from the start of dialysis and excluding CAPD training accounted for 62.5% of the year's admission.

Infections and antibiotics

Admission for infections accounted for between 23 and 46 days/dialysis/year and 2.4 and 6.9 admission episodes/year (Table I). Three of the patients also had minor infections treated on an out-patient basis,

Table I Hospital admissions

Patient	Number of admissions				Admissions for infection				Days for infection
	Total no	Admissions per year	Days	Days/y	Total	Admissions per year	Days	Days/y	Total days
1	6	10.3	34	58	4	6.9	27	46	79
2	6	4	39	26	4	2.7	34	23	87
3	14	10.5	92	74	6	4.5	50	37	54
4	6	4.8	48*	39	3	2.4	36	29	73
Mean		6.9		45.6		3.6		31.5	

*Excluding in patient number 4, 39 days for CAPD dialysis training.

Table II Sites of infection and antibiotic costings

Patient	No of infections		Admissions for infection	Site					Cost of antibiotics	
				Chest	Subclavian line	Peritonitis	Herpes	Other		
	Total	with neutropenia*							Total	per year
1	4	1	4	3	1	0	0	0	£332	£579
2	5	1	4	2	1	0	2	0	£308	£205
3	9	4	6	5	3	0	0	1	£510	£383
4	6	0	3	3	0	2	1	0	£392	£314
Total	24	6	17	13	5	2	3	1		

Patient 1 received prophylactic antibiotics during chemotherapy (see text).

*Total white count $< 3.0 \times 10^9/l$.

infection accounting for 54%–87% of admission days excluding training periods for CAPD (Table I). Only 6 (25%) of the total 24 infection episodes were associated with neutropenia (total white count $< 3.0 \times 10^9/l$). However, patient 3 had four infections (44%) associated with neutropenia. In the group as a whole, chest infections accounted for 54% of episodes with subclavian dialysis line infections 21%. All patients were initially dialysed via a temporary dual lumen subclavian cannula (Marhukher Quinton Ltd), the cannula being used for between one week (patient 4) to 6 months (patient 3).

The total cost of antibiotics ranged from £308.00 to £510.00 with an annual cost of £205.00 to £579.00 (Table II).

Blood products

Blood transfusions were given for symptomatic reasons and if the haemoglobin fell below 6.5 g/dl. All patients required regular and frequent transfusions with a range of 11 to 56 units/dialysis/year. Transfusion requirements were higher within the first 6

months of dialysis and during chemotherapy. Patient 1 received the greatest number of transfusions (33 units, 56/dialysis/year) but also had the most aggressive chemotherapy regime and the poorest paraprotein response. Plasma protein fraction (5%) was also given to three patients (3–17 bottles) to treat hypotension and hypoalbuminaemia during dialysis.

The costing of blood products ranged from £243–£988 per patient, corrected to £162–£1,018 per dialysis year, (Table III).

Costing

There was a wide range in the costing for each variable (Table III), the most expensive variable being dialysis itself with CAPD being markedly cheaper than haemodialysis. Chemotherapy accounted for the least cost with the differences between patients explained by the much higher price of intravenous agents as compared to oral melphalan and prednisolone.

'In-patient' costs reflecting the number of days in hospital was, apart from dialysis itself, the largest cost and also the most variable.

Table III Costs of different items in patients' care

Patient	Dialysis costs*		In-patient costs†		Antibiotics		Blood products		Chemotherapy		Overall	
	Total	per year	Total	yr	Total	yr	Total	yr	Total	yr	Total	yr
1	£10010	£17160	£2618	£4488	£338	£579	£594	£1018	£348	£597	£13908	£23842
2	£25740	£17160	£2002	£1334	£308	£205	£243	£162	£300	£200	£28593	£19062
3	£21450	£17160	£5313	£3985	£510	£383	£988	£741	£73	£55	£28334	£21250
4	£9089	£7161	£3696	£2952	£392	£314	£801	£640	£20	£16	£17601	£13603
Mean				£3564		£332		£563		£159		

*Dialysis costs, haemodialysis £110.00 per treatment, 4 CAPD 2 litre exchanges £19.92 per day; †Cost/day £77.00, (includes 39 days CAPD training for patient number 4).

Quality of life

Only one patient (number 3) was in full time employment when he presented with myeloma. Despite numerous admissions and the restrictions of maintenance haemodialysis he has managed to continue his business as a market gardener. Patient 2, a retired civil servant, experienced initial debility associated with chemotherapy though enjoys a full active retirement, recently holidaying in Portugal on dialysis. Patient 4, a sister in a convent, had to relinquish her duties of caring for other frail and elderly nuns to be looked after herself. Patient 1, a retired army sergeant major, never regained his pre-presentation state of health. He also suffered from episodes of depression associated with steroid therapy and infections and considered discontinuing treatment on two occasions.

Discussion

Historically, renal failure is second only to infection as the most common cause of death in multiple myeloma,¹² with renal insufficiency at presentation associated with a poor prognosis.¹³ More recently, it has been shown that with correction of dehydration,¹⁴ and prompt attention to reversible features, a significant number of patients can regain renal function.¹⁵

There does, however, remain a group of patients with multiple myeloma and chronic irreversible renal failure with either an acute or insidious onset. Such patients are accepted on chronic dialysis programmes. Myeloma accounts for 0.6% of patients 15–64 years of age and 1.7% patients > 65 years of age on the European Dialysis and Transplant Register in 1984–5.⁸ Myeloma is therefore more frequent than tuberculosis and approximately equal to systemic lupus erythematosus as a cause for chronic dialysis.

Cosio suggested that in patients with myeloma and chronic renal failure, the prevention of death by dialysis resulted in a prognosis similar to patients without renal insufficiency.¹ If this is the case, are the complications we experience similar to those in myeloma patients without renal insufficiency?

Bacterial infections are a major cause of morbidity and mortality in all myeloma patients with an incidence of 0.8 to 2.22 infections per patient/year,^{16,17} with lower respiratory tract infections being the most frequent, as also shown in our series. The data presented in this paper give an incidence of 2.4 to 6.9 infections per patient/year, higher than previous myeloma series, yet confirmed by a preliminary report by Tam *et al.*¹⁸ of 8 myeloma patients treated by CAPD with an average of 2.5 infections/year/patient with a range of 0–6.3. Such results would suggest that

myeloma patients on dialysis have a greater risk of infection than those without renal insufficiency, contradicting Cosio's statement.¹

Decreased clearance of anti-mitotic drugs in renal failure and possible marrow suppression could contribute to an increased risk of infection. This does not seem to be relevant as our observation is that only 25% of infections were associated with neutropenia.

Infections were more common within the first 3 months from presentation when the highest number of admissions occurred, a finding also observed by Perri *et al.*⁵ In our series, this could at least be partly accounted for by subclavian dialysis cannula exit site infections. Such infections are well recognized in non-myeloma patients and though our numbers are small, there does not appear to be an increased risk or contra-indication to the use of this technique.

Herpes infections have infrequently been described in patients with myeloma,^{19,20} yet two patients had three infections, all of which were of a minor nature and responded to acyclovir.

Our only CAPD patient had two episodes of peritonitis in 15 months, the same rate as a recent large study.²¹ The report by Tam *et al.*¹⁸ on myeloma patients gave an average peritonitis rate of 3.2 episodes per year with a range of 1.3 to 7.5 episodes per year. A worrying observation that needs further confirmation if CAPD is to be considered in treating such patients.

Costing of dialysis treatment depends on what is included, the type of dialysis and in which country the treatment is performed.^{6,22,23} Despite these differences, it is widely accepted that hospital based maintenance haemodialysis is more expensive than home dialysis whether it is CAPD or haemodialysis.

Our own figures of £110.00 per hospital haemodialysis treatment, and £19.32/day for CAPD are comparable with previously published figures.²⁵ Our costs in myeloma patients for maintenance haemodialysis of £19,062–£23,842 per annum and CAPD £13,600 per annum compare with published figures of £12,500–£15,300 for maintenance haemodialysis,²³ and £8,400–£11,000 for CAPD.²⁴ Using our audit costings and admission rates from the 7 centre dialysis study,²¹ we calculate maintenance haemodialysis at £18,146 per annum and CAPD at £8,403 per annum. This latter figure excludes training. The costs for the myeloma patients in our study are between 5% and 33% more expensive than these calculated figures. The costing differences in myeloma patients are due to the extra costs of chemotherapy, blood products, antibiotics and additional hospitalization. A major variable in the calculations is the number of admissions per year, a factor which we have shown is greatly increased in myeloma patients. The recent 7 centre dialysis study²¹ of 338 CAPD and 175 haemodialysis patients shows a hospitalization rate of

14.9 days per year on CAPD and 12.8 per year for haemodialysis patients. These figures are obviously much lower than our data.

An early report from the Mayo Clinic² suggested an average of 12 days hospitalization/year in their myeloma patients on chronic dialysis, whilst the Leicester experience¹⁸ gave 75 days hospitalization/patient with a range of 31–152 days. Our findings fit between these two extremes.

The duration of hospital admission adds greatly to the annual cost. We do not suggest that only myeloma patients are at risk of such admissions, yet it seems a common pattern both from Leicester and our own experience, that myeloma patients on chronic dialysis, have more frequent and longer durations of hospitalization.

References

- Cosio, F.G., Pence, T.V., Shapiro, F.P. & Kjellstrand, C.M. Severe renal failure in multiple myeloma. *Clin Nephrol* 1981, **15**: 206–210.
- Johnson, W.G., Kyle, R.A. & Dahlburg, P.J. Dialysis in the treatment of multiple myeloma. *Mayo Clin Proc* 1980, **55**: 65–72.
- Coward, R.A., Mallick, N.P. & Delamore, I.W. Should patients with renal failure associated with myeloma be dialysed? *Br Med J* 1983, **287**: 1575–1578.
- Jacobson, D.R. & Zolla-Pazner, S. Immunosuppression and infection in multiple myeloma. *Semin Oncol* 1986, **13**: 282–290.
- Perri, R.T., Hebbel, R.P. & Oken, M.M. Influence of treatment and response status on infection risk in multiple myeloma. *JAMA* 1981, **71**: 935–939.
- Wood, I.T., Mallick, N.P. & Wing, A.J. Prediction of resources needed to achieve the national target for treatment of renal failure. *Br Med J* 1987, **294**: 1467–1470.
- Williams, A. Coronary artery by-pass grafting, an economic appraisal. *Br Med J* 1985, **291**: 326–329.
- Report of E.D.T.A. Registry. Demography of dialysis and transplantation in Europe 1984. *Nephrol Dial Transplant* 1986, **1**: 1–8.
- Medical Research Council. Treatment comparisons in the third MRC myelomatosis trial. *Br J Cancer* 1980, **42**: 823–830.
- Anderson, H. Scarffe, J.H., Lambert, M. *et al.* VAD chemotherapy, toxicity and efficacy in patients with multiple myeloma and other lymphoid malignancies. *Haematol Oncol* in press.
- Barlogie, B., Smith, L. & Alexanian, R. Effective treatment of advanced multiple myeloma refractory to alkylating agents. *N Engl J Med* 1984, **310**: 1353–1356.
- Kyle, R.A. Multiple myeloma – A review of 869 cases. *Mayo Clin Proc* 1975, **50**: 29–40.
- Medical Research Council working party on leukaemia in adults. Prognostic features in the third MRC myelomatosis trial. *Br J Cancer* 1980, **42**: 831–840.
- Medical Research Council working party on leukaemia in adults. Analysis and management of renal failure in the fourth MRC myelomatosis trial. *Br Med J* 1984, **288**: 1411–1416.
- Rota, S., Manganot, B., Baudouin, B. *et al.* Multiple myeloma and severe renal failure: a clinico-pathological study of outcome and prognosis in 34 patients. *Medicine (Baltimore)* 1987, **66**: 126–137.
- Fahey, J.L., Scoggins, R., Utz, J.P. *et al.* Infections, antibody response and gamma globulin components in multiple myeloma and macroglobulinaemia. *Am J Med* 1963, **35**: 698–707.
- Twomey, J.T. Infections complicating multiple myeloma and chronic lymphocytic leukaemia. *Arch Int Med* 1973, **132**: 562–565.
- Tam, F., Russel, G.I., Smith, B.A. & Walls, J. CAPD in end stage renal failure due to myeloma. Abstract – *Proceedings International Society of Nephrology* 1987, 201.
- Wright, E.T., Winer, L. & Hills, B. Herpes zoster and malignancy. *Arch Dermatol* 1961, **84**: 242–244.
- Cohen, H.J. & Randle, R.W. Managing the complications of plasma cell myeloma. *Arch Intern Med* 1975, **135**: 177–184.
- Gokal, R., Baillard, R., Bogle, S. *et al.* Multicentre study on outcome of treatment in patients in continuous ambulatory peritoneal dialysis and haemodialysis. *Nephrol Dial Transplant* 1987, **2**: 172–178.
- Manis, T. & Friedman, E.A. Dialytic therapy for irreversible uremia. *N Engl J Med* 1979, **301**: 1260–1265.
- Mancini, P.V. The cost of treating end stage renal failure. Draft paper for DHSS, Elephant and Castle, London. June 1984.
- Beardsworth, S.F. & Goldsmith, H.J. CAPD on Merseyside – cost effectiveness. *Health Trends* 1982, **14**: 89–91.
- Durie, B.G.M. & Salmon, S.E. A clinical staging system for multiple myeloma. *Cancer* 1975, **36**: 842–854.

Acknowledgements

We would like to thank Miss Julie Marginson for typing the manuscript, Mr Mark Youlton for performing the internal audit, Miss Jane Boyland for costing the drugs and Dr N.P. Mallick for critical comments.